Best Grants for HIV / AIDS in District of Columbia

Nonprofit 501(c)(3) public charities serving DC-area residents with HIV/AIDS-related programs can seek funding to improve health, housing stability, and supportive services. Morris & Gwendolyn Cafritz Foundation supports work in HIV/AIDS, health care access, homelessness, and related community services in the Washington, DC metropolitan area, awarding US $10,000 - US $250,000 for impactful, comprehensive initiatives.

Certified substance use disorder providers in the District of Columbia can receive up to US $13,000 to deliver HIV early intervention services, including counseling, screening, and linkage to care. The District of Columbia Department of Behavioral Health supports HIV/AIDS prevention through education, testing, referrals to treatment, and data monitoring within its behavioral health provider network.

Certified substance use disorder providers in the District of Columbia can receive up to US $13,000 to deliver HIV early intervention services, including counseling, screening, and referrals. The District of Columbia Department of Behavioral Health funds prevention, testing, linkage to care, and data monitoring within its behavioral health provider network.

District of Columbia and Prince George's County housing and HIV service providers can receive funding for rental assistance and housing-related supportive services for low-income residents living with HIV. District of Columbia Department of Health provides District of Columbia HIV / AIDS organizations with US $300,000 - US $8,000,000 to expand stable, affordable housing and coordinated support that improve health outcomes.

Organizations providing rental assistance and housing-related supportive services for people living with HIV in the District of Columbia and nearby Maryland counties can apply for District of Columbia Department of Health’s Housing Opportunities for Persons with AIDS program, with awards from US $300,000 - US $8,000,000. Funding supports time-limited and facility-based housing, supportive services, and intensive case management to prevent homelessness and improve health outcomes.

Nonprofit and community health organizations in the District of Columbia can seek funding to deliver comprehensive HIV, STI, and hepatitis B/C prevention and screening services for populations most at risk. With a mission to promote public health, District of Columbia Department of Health provides $75,000 - $175,000 for culturally appropriate prevention, testing, and PrEP/PEP education programs.

The Robinson Foundation Grant, established in 2016, aims to alleviate hardships faced by individuals and communities, demonstrating God's love through charitable contributions. As a family-operated foundation, it focuses on creating meaningful, long-term impacts in various areas including animal welfare, education, and disaster relief. Organizations eligible for funding must be 501(c)(3) public charities. The foundation prioritizes fiscally responsible projects with the potential for tangible results, while not supporting capital projects.

Bristol Myers Squibb is dedicated to enhancing healthcare and advancing scientific knowledge through its Corporate Giving program. By supporting various organizations, BMS aims to improve health equity and access to essential medicines for underserved populations. Their focus includes charitable donations, medical education, and community support initiatives. This commitment reflects BMS's goal to make a positive impact on patients' lives and foster strong communities where their employees work and live.

District of Columbia HIV / AIDS researchers can access funding through the National Institutes of Health to study how HIV immunotherapies affect central nervous system outcomes. This R21/R33 opportunity offers up to US $2,000,000 for biphasic projects examining mechanisms, benefits, and risks, including CNS viral persistence, neurotoxicity, and neuroinflammation in people with HIV.

Research institutions and clinical organizations conducting HIV/AIDS prevention and treatment studies in the District of Columbia can access funding through the National Institutes of Health to operate Clinical Trials Units within NIAID’s HIV/AIDS Clinical Trials Networks. Awards support randomized clinical trials, implementation research, and infrastructure across domestic and international clinical research sites connected to these networks.

District of Columbia HIV research organizations with capacity to run large clinical trials can access funding through the National Institutes of Health to serve as Statistical and Data Management Centers. Awards support leadership in HIV clinical trial design, data collection and monitoring, analysis, and harmonized data systems across multi-site networks, including U.S. territories.

Research institutions and clinical laboratories working on HIV/AIDS prevention and treatment can apply for National Institutes of Health support to serve as Laboratory Centers within HIV/AIDS Clinical Trials Networks. These centers provide laboratory infrastructure, testing, data systems, and assay capacity for network trials, which may benefit HIV-focused organizations in the District of Columbia.

Research institutions focused on HIV/AIDS clinical trials can apply to lead one of four Clinical Trials Networks, guiding prevention, treatment, and implementation research. Focused on HIV/AIDS, the National Institutes of Health invites District of Columbia and other eligible organizations to direct Leadership and Operations Centers advancing strategies to end the HIV epidemic across the lifespan.

The NIDA Core "Center of Transformative Science" Grant Program aims to enhance research on substance use, addiction, and HIV by fostering collaboration among NIH-funded researchers. Centers are expected to innovate and extend existing research through shared resources and support for new investigators. This initiative encourages interdisciplinary work and aims to transform the scientific landscape by promoting data sharing and collaborative opportunities. Applications should focus on integrating research within a specific thematic framework to maximize impact.

This funding opportunity aims to advance HIV/AIDS research by implementing human new approach methodologies (NAMs) to reduce the reliance on specific pathogen free (SPF) animal models. It emphasizes the integration of NAMs-enabled frameworks for in vitro testing while supporting essential SPF colony resources. The initiative seeks to enhance research rigor and reproducibility through innovative strategies that prioritize human-relevant models, ultimately improving HIV research outcomes and facilitating collaborative development in the field.

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

The Ryan White HIV/AIDS Program (RWHAP) Integrated HIV/AIDS Planning Resource Allocation Cooperative Agreement aims to enhance the effectiveness of HIV prevention and care planning for RWHAP Parts A and B recipients. Through the provision of training, tools, and technical assistance, this initiative seeks to optimize resource allocation and strengthen the overall system of HIV care and treatment, ultimately improving health outcomes for those affected by HIV.

The AIDS Drug Assistance Program (ADAP) Emergency Relief Funds aim to provide essential funding to states and territories. This initiative focuses on preventing, reducing, or eliminating waiting lists for ADAP services, ensuring timely access to necessary medications and support for individuals living with HIV/AIDS. This program addresses critical funding shortfalls, enhancing the healthcare infrastructure and improving health outcomes in affected communities.

The Ryan White HIV/AIDS Program Part C Capacity Development Program aims to enhance the capabilities of community-based organizations, focusing on improving health outcomes and decreasing HIV transmission. This initiative supports individuals who have not yet accessed regular HIV care, emphasizing innovative care solutions and infrastructure development to address these critical needs.

The HIV Care Grant Program, funded by the US HHS: Health Resources & Services Administration (HRSA), aims to enhance access to high-quality HIV care and treatment for low-income individuals. This initiative supports states and territories in developing comprehensive systems to address the needs of those living with HIV. By providing essential resources, the program seeks to improve health outcomes and ensure that vulnerable populations receive the necessary support and services.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The HIV Care Grant Program aims to enhance access to comprehensive, high-quality HIV care and treatment for low-income individuals in Pacific Island territories. Funded by the US HHS: Health Resources & Services Administration (HRSA), this initiative supports states and territories in developing effective systems of care, ensuring that those affected by HIV receive the necessary treatment and support to improve health outcomes.

This funding opportunity aims to enhance a web-based ordering portal for distributing 1.5 million HIV and STI self-tests to high-burden communities. By optimizing access to these self-tests, the initiative seeks to raise awareness, prevent new infections, and improve the health outcomes of users, thereby contributing to better overall public health and wellbeing.

This project aims to enhance health outcomes for women living with HIV in the South by integrating HIV care with comprehensive women's health services through coordinated Clinic and Community Collaboratives. By funding organizations to implement targeted strategies such as culturally responsive services and learning collaboratives, the initiative seeks to improve access to essential health services, increase the number of women initiating rapid ART, and foster sustainable healthcare models that address the unique needs of this population.

The Ryan White HIV/AIDS Program Part D provides supplemental funding aimed at enhancing the infrastructure and capacity of organizations to deliver high-quality, family-centered HIV care services. This initiative focuses on two key areas: HIV Care Innovation and Infrastructure Development, ensuring improved access to essential services for women, infants, children, and youth affected by HIV.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

Gilead Sciences

At Gilead, we are relentlessly committed to advancing transformative therapies for the most serious diseases, delivering an exponentially positive impact on health.

For more than three decades, we have combined scientific rigor with a deep sense of purpose to improve health outcomes and reimagine care. Our work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation, where unmet medical needs remain greatest.

From individual patients to whole populations, we’re committed to delivering healthier futures for people and communities worldwide.

Our Mission: To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

HIV Prevention NOVA 2026

Program Description

Gilead Sciences invites research proposals that advance the evidence base for innovative and scalable models of delivery for long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the United States.

This Topic of Interest (TOI) is focused on care delivery models implemented in non-traditional settings, defined as clinical and non-clinical environments where PrEP services are not routinely provided. Emphasis is placed on approaches that reflect real-life practice and address gaps in current PrEP delivery infrastructure.

Persistent inequities in PrEP uptake in the U.S. suggest that expanding availability within traditional clinical settings alone is unlikely to reach all populations with unmet PrEP need.1,2 Rigorous implementation studies in non-traditional settings where PrEP services are not routinely provided are needed to evaluate whether these models can reduce access barriers and improve equitable reach among individuals who may benefit from PrEP.2,3,4

The goal of this TOI is to generate practical, decision-relevant evidence that informs how LA PrEP can be implemented, scaled, and sustained in real-life U.S. settings.